---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-023336"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2026-05-29T20:50:12+00:00"
generated_at: "2026-05-29T20:51:11.790073+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lisata amends merger: cash per share cut from $5 to $4, CVR increased to up to $3

## Summary
- Cash consideration reduced from $5.00 to $4.00 per share; CVR now offers up to $3.00 total ($1.25 + $1.75 milestone payments).
- Tender offer to commence June 1, 2026; outside date extended from July 1 to July 6, 2026.
- First CVR milestone ($1.25) tied to completion/90% enrollment of Phase 2a GBM study; second ($1.75) to NDA filing.
- Original CVR was a single $1.00 contingent payment; new structure adds potential $2.00 upside but lowers upfront cash.

## SEC filing metadata
- accession: 0001140361-26-023336
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2026-05-29T20:50:12+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000114036126023336/0001140361-26-023336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000114036126023336/ef20075162_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-023336
- JSON: https://secwatch.observer/filing/0001140361-26-023336.json
- Plain text: https://secwatch.observer/filing/0001140361-26-023336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.